Selected attributes of polyphenols in targeting oxidative stress in cancer

Current Topics in Medicinal Chemistry

Volumn 15, Issue 5, 2015, Pages 496-509

  Stepanić, Višnja ^a   Gašparović, Ana Čipak ^a   Trošelj, Koraljka Gall ^a   Amić, Dragan ^b   Žarković, Neven ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

Author keywords

Adjuvant; Anticancer therapy; Antioxidative; Curcumin; EGCG; Flavonoids; NRF2; Polyphenols; Pro oxidative

Indexed keywords

ADJUVANT; ANTIOXIDANT; APIGENIN; ASCORBIC ACID; CATECHOL; CHRYSIN; CISPLATIN; CURCUMIN; CYTOSTATIC AGENT; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; FREE RADICAL; GENISTEIN; GLUTATHIONE; IMATINIB; LUTEOLIN; METHOTREXATE; PACLITAXEL; POLYPHENOL; PYROGALLOL; QUERCETIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESORCINOL; RESVERATROL; SCAVENGER; TRANSCRIPTION FACTOR NRF2; UNINDEXED DRUG; VINCRISTINE; XANTHINE OXIDASE; ANTINEOPLASTIC AGENT; FLAVONOID; NFE2L2 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL LINE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHEMOSENSITIVITY; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DRUG EFFICACY; HUMAN; IC50; INFLAMMATION; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN EXPRESSION; SCAVENGING SYSTEM; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; AGONISTS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CYTOSTATIC AGENTS; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; FREE RADICALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUTEOLIN; NADPH OXIDASE; NEOPLASMS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; POLYPHENOLS; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINE OXIDASE;

EID: 84937120344     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150209123100     Document Type: Article

References (125)

1. Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm (Accessed July 4, 2014).
2. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted (Accessed December 15, 2014)
3. Pignatti, F.; Jonsson, B.; Blumenthal, G.; Justice R. Assessment of benefits and risks in development of targeted therapies for cancer-The view of regulatory authorities. Mol. Oncol., 2014, DOI: http://dx.doi.org/10.1016/j.molonc.2014.10.003
4. Rang, H.P.; Dale M.M.; Ritter J.M.; Flower R.J. Rang & Dale's Pharmacology, 6th Ed.; Elsevier: Edinburgh, 2007.
5. Lawenda, B.D.; Kelly, K.M.; Ladas, E.J.; Sagar, S.M.; Vickers, A.; Blumberg J.B. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J. Natl. Cancer Inst., 2008, 100(11), 773-783.
6. Ramanathan, B.; Jan, K.Y.; Chen, C.H.; Hour, T.C.; Yu, H.J.; Pu, Y.S. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res., 2005, 65(18), 8455-8460.
7. Benedict, W.F.; Banerjee, A.; Venkatesan, N. Cyclophosphamideinduced oncogenic transformation, chromosomal breakage, and sister chromatid exchange following microsomal activation. Cancer Res., 1978, 38(9), 2922-2924.
8. Zheng, J.; Lee, H.C.; Bin Sattar, M.M.; Huang, Y.; Bian, J.S. Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury. Eur. J. Pharmacol., 2011, 652(1-3), 82-88.
9. Domitrović, R.; Cvijanović, O.; Pugel, E.P.; Zagorac, G.B.; Mahmutefendić, H.; Škoda, M. Luteolin ameliorates cisplatininduced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney. Toxicology, 2013, 310, 115-123.
10. Khurana, S.; Piche, M.; Hollingsworth, A.; Venkataraman, K.; Tai, T.C. Oxidative stress and cardiovascular health: therapeutic potential of polyphenols. Can. J. Physiol. Pharmacol., 2013, 91(3), 198-212.
11. Gupta, S.C.; Tyagi, A.K.; Deshmukh-Taskar, P.; Hinojosa, M.; Prasad, S.; Aggarwal, B.B. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch. Biochem. Biophys., 2014, 559, 91-99.
12. Stepanić V.; Novak Kujundžić R.; Gall Trošelj K. In: Epigenetics and Epigenomics; Payne, C., Ed.; InTech: Rijeka, 2014; pp. 173-209.
13. Bentires-Alj, M.; Barbu, V.; Fillet, M.; Chariot, A.; Relic, B.; Jacobs, N.; Gielen, J.; Merville, M.P.; Bour, V. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene, 2003, 22(1), 90-97.
14. Duan, J.; Mansour, H.M.; Zhang, Y.; Deng, X.; Chen, Y.; Wang, J.; Pan, Y.; Zhao, J. Reversion of multidrug resistance by coencapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int. J. Pharm., 2012, 426(1-2), 193-201.
15. Sreekanth, C.N.; Bava, S.V.; Sreekumar, E.; Anto, R.J. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene, 2011, 30(28), 3139-3152.
16. Gall Trošelj, K.; Kujundžić Novak, R. Curcumin in combined cancer therapy. Curr. Pharm. Des., 2014, 20(42), 6682-6696.
17. Kim, T.H.; Shin, Y.J.; Won, A.J.; Lee, B.M.; Choi, W.S.; Jung, J.H.; Chung, H.Y.; Kim, H.S. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim. Biophys. Acta, 2014, 1840(1), 615-625.
18. Wang, X.J.; Sun, Z.; Villeneuve, N.F.; Zhang, S.; Zhao, F.; Li, Y.; Chen, W.; Yi, X.; Zheng, W.; Wondrak, G.T.; Wong, P.K.; Zhang, D.D. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis, 2008, 29(6), 1235-1243.
19. Del Rio, D.; Rodriguez-Mateos, A.; Spencer, J.P.; Tognolini, M.; Borges, G.; Crozier, A. Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid. Redox Signal., 2013, 18(14), 1818-1892.
20. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol., 2007, 39(1), 44-84.
21. Paschos, A.; Pandya, R.; Duivenvoorden, W.C.M.; Pinthus, J.H. Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics. Prost. Cancer Prost. Dis., 2013, 16(3), 217-225.
22. Halliwell, B.; Clement, M.V.; Long, L.H. Hydrogen peroxide in the human body. FEBS Lett., 2000, 486(1), 10-13.
23. Dröge, W. Free radicals in the physiological control of cell function. Physiol. Rev., 2002, 82(1), 47-95.
24. Park, J.E.; Yang, J.H.; Yoon, S.J.; Lee, J.H.; Yang, E.S.; Park, J.W. Lipid peroxidation-mediated cytotoxicity and DNA damage in U937 cells. Biochimie, 2002, 84(12), 1199-1205.
25. Wallace, S.S. Biological consequences of free radical-damaged DNA bases. Free Radic. Biol. Med., 2002, 33(1), 1-14.
26. Jung, T.; Höhn, A.; Grune, T. The proteasome and the degradation of oxidized proteins: Part III-Redox regulation of the proteasomal system. Redox Biol., 2014, 2, 388-394.
27. Jones, D.P. Redox sensing: orthogonal control in cell cycle and apoptosis signalling. J. Intern. Med., 2010, 268(5), 432-448.
28. Jones, D.P. Radical-free biology of oxidative stress. Am. J. Physiol. Cell Physiol., 2008, 295(4), C849-C868.
29. von Montfort, C.; Sharov, VS.; Metzger, S.; Schöneich, C.; Sies, H.; Klotz, L.O. Singlet oxygen inactivates protein tyrosine phosphatase-1B by oxidation of the active site cysteine. Biol. Chem., 2006, 387(10-11), 1399-1404.
30. Čipak Gašparović, A.; Lovaković, T.; Žarković, N. Oxidative stress and antioxidants: biological response modifiers of oxidative homeostasis in cancer. Period. Biol., 2010, 112(4), 433-439.
31. Trachootham, D.; Lu, W.; Ogasawara, M.A.; Nilsa, R.-D.V.; Huang, P. Redox regulation of cell survival. Antioxid. Redox Signal., 2008, 10(8), 1343-1374.
32. Jung, K.-A.; Kwak, M.-K. The Nrf2 system as a potential target for the development of indirect antioxidants. Molecules, 2010, 15(10), 7266-7291.
33. Augustyniak, A.; Bartosz, G.; Čipak, A.; Duburs, G.; Horáková, L.; Luczaj, W.; Majekova, M.; Odyssoes, A.D.; Rackova, L.; Skrzydlewska, E.; Stefek, M.; Štrosová, M.; Tirzitis, G.; Venskutonis, P.R.; Viskupicova, J.; Vraka, P.S.; Žarković, N. Natural and synthetic antioxidants: an updated overview. Free Radic. Res., 2010, 44(10), 1216-1262.
34. Adachi, T.; Nakagawa, H.; Chung, I.; Hagiya, Y.; Hoshijima, K.; Noguchi, N.; Kuo, M.T.; Ishikawa, T. Nrf2-dependent and-independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J. Exp. Ther. Oncol., 2007, 6(4), 335-348.
35. Bryan, H.K.; Olayanju, A.; Goldring, C.E.; Park, B.K.The Nrf2 cell defence pathway: Keap1-dependent and-independent mechanisms of regulation. Biochem. Pharmacol., 2013, 85(6), 705-717.
36. Sporn, M.B; Liby, K.T. NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer., 2012, 12(8), 564-571.
37. Bao, L.J.; Jaramillo, M.C.; Zhang, Z.B.; Zheng, Y.X.; Yao, M.; Zhang, D.D.; Yi, X.F. Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Int. J. Clin. Exp. Pathol., 2014, 7(4), 1502-1513.
38. Jaramillo, M.C.; Zhang, D.D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev., 2013, 27(20), 2179-2191.
39. Fang, J.; Lu, J.; Holmgren, A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J. Biol. Chem., 2005, 280(26), 25284-25290.
40. Dangles, O. Antioxidant activity of plant phenols: chemical mechanisms and biological significance. Curr. Org. Chem., 2012, 16(6), 692-714.
41. Sosa, V.; Moliné, T.; Somoza, R.; Paciucci, R.; Kondoh, H.; Lleonart, M.E. Oxidative stress and cancer: an overview. Ageing Res. Rev., 2013, 12(1), 376-390.
42. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5) 646-674.
43. Mahalingaiah, P.K.; Singh, K.P. Chronic oxidative stress increases growth and tumorigenic potential of MCF-7 breast cancer cells. PLoS One, 2014, 9(1), e87371.
44. Toyokuni, S.; Okamoto, K.; Yodoi, J.; Hiai, H. Persistent oxidative stress in cancer. FEBS Lett., 1995, 358(1), 1-3.
45. Reuter, S.; Gupta, S.C.; Chaturvedi, M.M.; Aggarwal, B.B. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med., 2010, 49(11), 1603-1616.
46. Maraldi T. Natural compounds as modulators of NADPH oxidases. Oxid. Med. Cell. Longev., 2013, 2013, ID 271602.
47. Federico, A.; Morgillo, F.; Tuccillo, C.; Ciardiello, F.; Loguercio, C. Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer, 2007, 121(11), 2381-2386.
48. Kujundžić Novak, R.; Žarković N.; Gall Trošelj K. Pyridine nucleotides in regulation of cell death and survival by redox and nonredox reactions. Crit. Rev. Eukaryot. Gene Expr., 2014, 24(4), 287-309.
49. Kamp, D.W.; Shacter, E.; Weitzman, S.A. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park), 2011, 25(5), 400-413.
50. Cai, Y.Z.; Sun. M.; Xing, J.; Luo, Q.; Corke, H. Structure-radical scavenging activity relationships of phenolic compounds from traditional Chinese medicinal plants. Life Sci., 2006, 78(25), 2872-2888.
51. Stepanić, V.; Gall Trošelj, K.; Lučić, B.; Marković, Z.; Amić, D. Bond dissociation free energy as a general parameter for flavonoid radical scavenging activity. Food Chem., 2013, 141(2), 1562-1570.
52. Lamoral-Theys, D.; Pottier, L.; Dufrasne, F.; Nève, J.; Dubois, J.; Kornienko, A.; Kiss, R.; Ingrassia, L. Natural polyphenols that display anticancer properties through inhibition of kinase activity. Curr. Med. Chem., 2010, 17(9), 812-825.
53. Boly, R.; Gras, T.; Lamkami, T.; Guissou, P.; Serteyn, D.; Kiss, R.; Dubois, J. Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int. J. Oncol., 2011, 38(3), 833-842.
54. Wang, Y.J.; Pan, M.H.; Cheng, A.L.; Lin, L.I.; Ho, Y.S.; Hsieh, C.Y.; Lin, J.K. Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal., 1997, 15(12), 1867-1876.
55. de Boer, V.C.J.; de Goffau, M.C.; Arts, I.C.W.; Hollman, P.C.H.; Keijer, J. SIRT1 stimulation by polyphenols is affected by their stability and metabolism. Mech. Ageing Dev., 2006, 127(7), 618-627.
56. Chiou, Y.S.; Wu, J.C.; Huang, Q.; Shahidi, F.; Wang, Y.J.; Ho, C.T.; Pan, M.H, Metabolic and colonic microbiota transformation may enhance the bioactivities of dietary polyphenols. J. Funct. Foods, 2014, 7(1), 3-25.
57. Day, A.J.; Bao, Y.; Morgan, M.R.; Williamson, G. Conjugation position of quercetin glucuronides and effect on biological activity. Free Radic. Biol. Med., 2000, 29(12), 1234-1243.
58. Kawai, Y.; Nishikawa, T.; Shiba, Y.; Saito, S.; Murota, K.; Shibata, N.; Kobayashi, M.; Kanayama, M.; Uchida, K.; Terao, J. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J. Biol. Chem., 2008, 283(14), 9424-9434.
59. Kawai Y. β-Glucuronidase activity and mitochondrial dysfunction: the sites where flavonoid glucuronides act as anti-inflammatory agents. J. Clin. Biochem. Nutr., 2014, 54(3), 145-150.
60. Ishisaka, A.; Kawabata K.; Miki S.; Shiba, Y.; Minekawa, S.; Nishikawa, T.; Mukai, R.; Terao, J.; Kawai, Y. Mitochondrial dysfunction leads to deconjugation of quercetin glucuronides in inflammatory macrophages. PLoS One, 2013, 8(11), e80843.
61. Son, T.G.; Camandola, S.; Mattson, M.P. Hormetic dietary phytochemicals. Neuromolecular Med., 2008, 10(4), 236-246.
62. Vargas, A.J.; Burd, R. Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr. Rev., 2010, 68(7), 418-428.
63. de Moura, C.F.G.; Noguti J.; de Jesus, G.P.P.; Ribeiro, F.A.P; Garcia, F.A.; Gollucke, A.P.B.; Aguiar, O.; Ribeiro, D.A. Polyphenols as a chemopreventive agent in oral carcinogenesis: putative mechanisms of action using in-vitro and in-vivo test systems. Eur. J. Cancer Prev., 2013, 22(5), 467-472.
64. Amorati, R.; Foti, M.C.; Valgimigli, L. Antioxidant activity of essential oils. J. Agric. Food Chem., 2013, 61(46), 10835-10847.
65. Pietta, P.-G., Flavonoids as antioxidants. J. Nat. Prod., 2000, 63(7), 1035-1042.
66. Wright, J.S.; Johnson, E.R.; DiLabio, G.A. Predicting the activity of phenolic antioxidants: theoretical method, analysis of substituent effects, and application to major families of antioxidants. J. Am. Chem. Soc., 2001, 123(6), 1173-1183.
67. Litwinienko, G.; Ingold, K. U. Solvent effects on the rates and mechanisms of reaction of phenols with free radicals. Acc. Chem. Res., 2007, 40(3), 222-230.
68. Weinberg, D.R.; Gagliardi, C.J.; Hull, J.F.; Murphy, C.F.; Kent, C.A.; Westlake, B.C.; Paul, A.; Ess, D.H.; McCafferty, D.G.; Meyer, T.J. Proton-coupled electron transfer. Chem. Rev., 2012, 112(7), 4016-4093.
69. Alberto, M.E.; Russo, N.; Grand, A.; Galano, A. A physicochemical examination of the free radical scavenging activity of Trolox: mechanism, kinetics and influence of the environment. Phys. Chem. Chem. Phys., 2013, 15(13), 4642-4650.
70. Li, D.D.; Han, R.M.; Liang, R.; Chen, C.H.; Lai, W.; Zhang J.P.; Skibsted, L.H. Hydroxyl radical reaction with trans-resveratrol: initial carbon radical adduct formation followed by rearrangement to phenoxyl radical. J. Phys. Chem. B., 2012, 116(24), 7154-7161.
71. Amić, A.; Marković, Z.; Dimitrić Marković, J.M.; Stepanić, V.; Lučić, B.; Amić, D. Towards an improved prediction of the free radical scavenging potency of flavonoids: the significance of double PCET mechanisms. Food Chem., 2014, 152, 578-585.
72. de Souza, R.F.V.; De Giovani, W.F. Antioxidant properties of complexes of flavonoids with metal ions. Redox Rep., 2004, 9(2), 97-104.
73. Moridani, M.Y.; Pourahmad, J.; Bui, H.; Siraki, A.; O'Brien, P.J. Dietary flavonoid iron complexes as cytoprotective superoxide radical scavengers. Free Radic. Biol. Med., 2003, 34(2), 243-253.
74. Kostyuk, V.A.; Potapovich, A.I.; Strigunova, E.N.; Kostyuk, T.V.; Afanasev, I.B. Experimental evidence that flavonoid metal complexes may act as mimics of superoxide dismutase. Arch. Biochem. Biophys., 2004, 428(2), 204-208.
75. Barik, A.; Mishra, B.; Shen, L.; Mohan, H.; Kadam, R.M.; Dutta, S.; Zhang, H.-Y.; Priyadarsini, K.I. Evaluation of a new copper(II)-curcumin complex as superoxide dismutase mimic and its free radical reactions. Free Radic. Biol. Med., 2005, 39(6), 811-822.
76. Lambert, J.D.; Elias, R.J. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch. Biochem. Biophys., 2010, 501(1), 65-72.
77. Lin, J.K.; Chen, P.C.; Ho, C.T.; Lin-Shian, S.Y. In: Free Radicals in Food; Morello, M.; Shahidi, F.; Ho, V.T., Eds.; ACS Symposium Series; American Chemical Society: Washington, DC, 2002; pp. 264-281.
78. Hunyadi, A.; Martins, A.; Danko, B.; Chuang, D.-W.; Trouillas, P.; Chang, F.-R.; Wu, Y.-C.; Falkay G. Discovery of the first nonplanar flavonoid that can strongly inhibit xanthine oxidase: protoapigenone 1'-O-propargyl ether. Tetrahedron Lett., 2013, 54(48), 6529-6532.
79. Block, K.I.; Koch, A.C.; Mead, M.N.; Tothy, P.K.; Newman, R.A.; Gyllenhaal, C. Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int. J. Cancer, 2008, 123(6), 1227-1239.
80. Heaney, M.L.; Gardner, J.R.; Karasavvas, N.; Golde, D.W.; Scheinberg, D.A.; Smith, E.A.; O'Connor, O.A. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res., 2008, 68(19), 8031-8038.
81. Fukui, M.; Yamabe, N.; Zhu, B.T. Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur. J. Cancer, 2010, 46(10), 1882-1891.
82. Alexandre, J.; Hu, Y.; Lu, W.; Pelicano, H.; Huang, P. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res., 2007, 67(8), 3512-3517.
83. Wang, G.-Q.; Dawsey, S.M.; Li, J.-Y.; Taylor, P.R.; Li, B.; Blot, W.J.; Weinstein, W.M.; Liu, F.S.; Lewin, K.J.; Wang, H.; Wiggett, S.; Gail, M.H.; Yang C.S. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the General Population Trial in Linxian, China. Cancer Epidemiol. Biomarkers Prev., 1994, 3(2), 161-166.
84. Taylor, P.R.; Li, B.; Dawsey, S.M.; Li, J.Y.; Yang, C.S.; Guo, W.; Blot, W.J. Prevention of esophageal cancer: the nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group. Cancer Res., 1994, 54(7 Suppl), 2029s-2031s.
85. Limburg, P.; Qiao, Y.; Mark, S.; Wang, G.; Perez-Perez, G.; Blaser, M.; Wu, Y.; Zou, X.; Dong, Z.; Taylor, P.; Dawsey, S. Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. J. Natl. Cancer Inst., 2001, 93(3), 226-233.
86. Rieke, C.; Papendieck, A.; Sokolova, O.; Naumann, M. Helicobacter pylori-induced tyrosine phosphorylation of IKKβ contributes to NF-κB activation. Biol. Chem., 2011, 392(4), 387-393.
87. Huang, F.Y.; Chan, A.O.; Rashid, A.; Wong, D.K.; Cho, C.H.; Yuen, M.F. Helicobacter pylori induces promoter methylation of E-cadherin via interleukin-1β activation of nitric oxide production in gastric cancer cells. Cancer, 2012, 118(20), 4969-4980.
88. Speciale, A.; Chirafisi, J.; Saija, A.; Cimino, F. Nutritional antioxidants and adaptive cell responses: an update. Curr. Mol. Med., 2011, 11(9), 770-789.
89. Tanigawa, S.; Fujii, M.; Hou, D.X. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. Free Radic. Biol. Med., 2007, 42(11), 1690-1703.
90. Granado-Serrano, A.B.; Martín, M.A.; Bravo, L.; Goya, L.; Ramos, S. Quercetin modulates Nrf2 and glutathione-related defenses in HepG2 cells: Involvement of p38. Chem. Biol. Interact., 2012, 195(2), 154-164.
91. Chian, S.; Thapa, R.; Chi, Z.; Wang, X.J.; Tang, X. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo. Biochem. Biophys. Res. Commun., 2014, 447(4), 602-608.
92. DeNicola, G.M.; Karreth, F.A.; Humpton, T.J.; Gopinathan, A.; Wei, C.; Frese, K.; Mangal, D.; Yu, K.H.; Yeo, C.J.; Calhoun, E.S.; Scrimieri, F.; Winter, J.M.; Hruban, R.H. Iacobuzio-Donahue, C.; Kern, S.E.; Blair, I.A.; Tuveson, D.A. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 2011, 475(7354), 106-109.
93. Tang, X.; Wang, H.; Fan, L.; Wu, X.; Xin, A.; Ren, H.; Wang, X.J. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic. Biol. Med., 2011, 50(11), 1599-1609.
94. Chian, S.; Li, Y.Y.; Wang, X.J.; Tang, X.W. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway. Asian Pac. J. Cancer Prev., 2014, 15(6), 2911-2916.
95. Gao, A.M.; Ke, Z.P.; Wang, J.N.; Yang, J.Y.; Chen, S.Y.; Chen, H. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis, 2013, 34(8), 1806-1814.
96. Gao, A.M.; Ke, Z.P.; Shi, F.; Sun, G.C.; Chen, H. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem. Biol. Interact., 2013, 206(1), 100-108.
97. Hu, L.; Miao, W.; Loignon, M.; Kandouz, M.; Batist, G. Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. Cancer Chemother. Pharmacol., 2010, 66(3), 467-474.
98. Quideau, S.; Deffieux, D.; Douat-Casassus, C.; Pouysegu, L. Plant polyphenols: chemical properties, biological activities, and synthesis. Angew. Chem. Int. Ed., 2011, 50(3), 586-621.
99. Chu, K.O.; Chan, S.-O.; Pang, C.P.; Wang, C.C. Pro-oxidative and antioxidative controls and signaling modification of polyphenolic phytochemicals: contribution to health promotion and disease prevention? J. Agric. Food Chem., 2014, 62(18), 4026-4038.
100. Fukumoto, L.R.; Mazza, G. Assessing antioxidant and prooxidant activities of phenolic compounds. J. Agric. Food Chem., 2000, 48(8), 3597-3604.
101. Kim, H.S.; Quon, M.J.; Kim, J.A. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol., 2014, 2, 187-195.
102. Hadi, S.M.; Bhat, S.H.; Azmi, A.S.; Hanif, S.; Shamim, U.; Ullah, M.F. Oxidative breakage of cellular DNA by plant polyphenols: a putative mechanism for anticancer properties. Semin. Cancer Biol., 2007, 17(5), 370-376.
103. Chang, Y.F.; Chi, C.W.; Wang, J.J. Reactive oxygen species production is involved in quercetin-induced apoptosis in human hepatoma cells. Nutr. Cancer, 2006, 55(2), 201-209.
104. Hussain, H.H.; Babic, G.; Durst, T.; Wright, J.S.; Flueraru, M.; Chichirau, A.; Chepelev, L.L. Development of novel antioxidants: design, synthesis, and reactivity. J. Org. Chem., 2003, 68(18), 7023-7032.
105. Robaszkiewicz, A.; Balcerczyk, A.; Bartosz, G. Antioxidative and prooxidative effects of quercetin on A549 cells. Cell Biol. Int., 2007, 31(10), 1245-1250.
106. Smith, N.A.; Byl, J.A.; Mercer, S.L.; Deweese, J.E.; Osheroff, N. Etoposide quinone is a covalent poison of human topoisomerase IIβ. Biochemistry, 2014, 53(19), 3229-3236.
107. Bolton, J.L.; Thatcher, G.R. Potential mechanisms of estrogen quinone carcinogenesis. Chem. Res. Toxicol., 2008, 21(1), 93-101.
108. Doroshow J.H. Reductive activation of mitomycin C: a delicate balance. J. Natl. Cancer Inst., 1992, 84(15), 1138-1139.
109. Metodiewa, D.; Jaiswal, A.; Cenas, N.; Dickancaite, E.; Segura-Aguilar, J. Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product. Free Radic. Biol. Med., 1999, 26(1-2), 107-116.
110. Martin, K.R.; Appel, C.L. Polyphenols as dietary supplements: A double-edged sword, Nutr. Diet. Suppl., 2010, 2, 1-12.
111. Villaño, D.; Fernández-Pachón, M.S.; Moyá, M.L.; Troncoso, A.M.; García-Parrilla, M.C. Radical scavenging ability of polyphenolic compounds towards DPPH free radical. Talanta, 2007, 71(1), 230-235.
112. Bolton, J.L.; Pisha, E.; Shen, L.; Krol, E.S.; Iverson, S.L.; Huang, Z.; van Breemen, R.B.; Pezzuto, J.M. The reactivity of o-quinones which do not isomerize to quinone methides correlates with alkylcatechol-induced toxicity in human melanoma cells. Chem. Biol. Interact., 1997, 106(2), 133-148.
113. Tu, T.; Giblin, D.; Gross, M.L. Structural determinant of chemical reactivity and potential health effects of quinones from natural products. Chem. Res. Toxicol., 2011, 24(9), 1527-1539.
114. Yamashita, N.; Kawanishi, S. Distinct mechanisms of DNA damage in apoptosis induced by quercetin and luteolin. Free Radic. Res., 2000, 33(5), 623-633.
115. Wätjen, W.; Michels, G.; Steffan, B.; Niering, P.; Chovolou, Y.; Kampkötter, A.; Tran-Thi, Q.-H.; Proksch, P.; Kahl, R. Low concentrations of flavonoids are protective in rat HAIIE cells whereas high concentrations cause DNA damage and apoptosis. J. Nutr., 2005, 135(3), 525-531.
116. Samuel, T.; Fadlalla, K.; Turner, T.; Yehualaeshet, T.E. The flavonoid quercetin transiently inhibits the activity of taxol and nocodazole through interference with the cell cycle. Nutr. Cancer, 2010, 62(8), 1025-1035.
117. Jackman, M.; Lindon, C.; Nigg, EA.; Pines, J. Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat. Cell. Biol., 2003, 5(2), 143-148.
118. Choi, J.S.; Jo, B.W.; Kim, Y.C. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J. Pharm. Biopharm., 2004, 57(2), 313-318.
119. Choi, J.S.; Piao, Y.J.; Kang, K.W. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch. Pharm. Res., 2011, 34(4), 607-613.
120. Li, G.X.; Chen, Y.K.; Hou, Z.; Xiao, H.; Jin, H.; Lu, G.; Lee, M.J.; Liu, B.; Guan, F.; Yang, Z.; Yu, A.; Yang, C.S. Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis, 2010, 31(5), 902-910.
121. Nakagawa, H.; Hasumi, K.; Woo, J.T.; Nagai, K.; Wachi, M. Generation of hydrogen peroxide primarily contributes to the induction of Fe(II)-dependent apoptosis in Jurkat cells by (-)-epigallocatechin gallate. Carcinogenesis, 2004, 25(9), 1567-1574.
122. Winterbourn, C.C. The biological chemistry of hydrogen peroxide. In: Methods in Enzymology; Cadenas, E.; Packer, L., Eds.; Academic Press: Burlington, 2013; Vol. 528, pp. 3-25.
123. Kweon, M.H.; Adhami, V.M.; Lee, J.S.; Mukhtar, H. Constitutive overexpression of Nrf2 dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J. Biol. Chem., 2006, 281(44), 3361-3372.
124. Na, H.K.; Surh, Y.J. Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food Chem. Toxicol., 2008, 46(4), 1271-1278.
125. Amin, A.R.; Wang, D.; Zhang, H.; Peng, S.; Shin, H.J.; Brandes, J.C.; Tighiouart, M.; Khuri, F.R.; Chen, Z.G.; Shin, D.M. Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J. Biol. Chem., 2010, 285(45), 34557-34565.